Consistent consideration of cancer family history and genetic test status will dramatically change your medical management recommendations for all patient types. There are two essential steps to identify your patients for Hereditary Cancer Risk in order to optimize your medical management:

Screen and Evaluate.

Screen

Cancer family history questionnaire

Ask each patient to fill one out to capture 3 degrees of cancer history for both maternal and paternal family members. Emphasizing to your patients the importance of capturing a thorough family history will allow you to better evaluate their hereditary cancer risk and appropriateness for testing.

Evaluate

Review your patient's Cancer Family History using consistent red flags to determine if your patient is at increased risk for hereditary cancers.

Red Flags for Patients

Multiple

A combination of cancers on the same side of the family
  • 2 or more: breast / ovarian / prostate / pancreatic cancer
  • 2 or more: colorectal / endometrial / ovarian / gastric / pancreatic / other cancers (i.e., ureter/renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas)
  • 2 or more: melanoma / pancreatic cancer

Young

Any one of the following cancers at age 50 or younger
  • Breast cancer
  • Colorectal cancer
  • Endometrial cancer

Rare

Any one of these rare presentations at any age
  • Ovarian cancer
  • Breast: male breast cancer or triple negative breast cancer
  • Colorectal cancer with abnormal MSI/IHC, MSI associated histology††
  • Endometrial cancer with abnormal MSI/IHC
  • 10 or more gastrointestinal polyps*
Certain ancestries may have greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry)

Assessment criteria based on medical society guidelines. For these individual medical society guidelines, go to www.MyriadPro.com/guidelines.
Family members include first-, second-, and third-degree blood relatives on both your mother’s and father’s sides.

*Adenomatous type. ††Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.

**For the most up-to-date general population, gene-associated cancer risks, management criteria, and other syndrome-related cancers not listed here refer to the Gene Tables located at https://www.MyriadPro.com/myRisk Risks are for patients who have never had cancer. Patients with hereditary risk may have increased risk for other syndrome related cancers.

Myriad, the Myriad logo, Myriad myRisk and the Myriad myRisk logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.

©2015, Myriad Genetic Laboratories, Inc. MRHCBDGB/4-15